Print
Email
Print Edition Stories
MHT's Kyle Alspach: Young entrepreneurs & Osmopure's water filtration tech
2011 Women to Watch: Nina Dudnik
MHT's Galen Moore: Boston startups get creative with real estate
Biotech Acetylon Pharmaceuticals Inc. is moving from its Albany Street location in Boston to the Seaport Center near the South Boston waterfront.
Acetylon is developing selective small molecule histone deacetylase (HDAC) inhibitors and other targeted drugs for the treatment of cancers, and for inflammatory, neurodegenerative, genetic and infectious diseases.
The company has leased 9,700 square feet of space for its new headquarters, including office and lab space, as well as two biosafety level 2 labs that are scheduled to be completed this summer. According to realtor Jones Lang LaSalle, which represented the property owner Beal Companies, Acetylon is the first R&D tenant in Seaport Center.
The news came just a week after Acetylon bumped up its Series B funding to $27 million, and closed the round short of its initial stated goal of $30 million.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
